市場調查報告書
商品編碼
1411269
植入式心臟復律去顫器市場- 按產品(經靜脈ICD、皮下ICD)、按類型(單腔、雙腔、雙心室設備)、最終用途(醫院、門診手術中心)和預測,2024- 2032 年Implantable Cardioverter Defibrillators Market - By Product (Transvenous ICDs, Subcutaneous ICDs), By Type (Single-Chamber, Dual-Chamber, Biventricular Devices), End-use (Hospitals, Ambulatory Surgical Centers) & Forecast, 2024-2032 |
預計從2024 年到2032 年,植入式心律轉復除顫器市場規模將增加6.4% 以上。心血管疾病,特別是心律不整和心臟驟停的盛行率不斷增加,正在推動對植入式心律轉復除顫器(ICD) 的需求。人口老化和生活方式相關風險因素的增加正在導致 ICD 技術不斷進步。例如,2023 年 12 月,PROFID EHRA 研究啟動,這是第一個重新評估在患有心臟衰竭的心臟病倖存者中植入除顫器的標準做法的臨床試驗。
人們對預防性醫療措施的認知不斷提高,加上有利的報銷政策的湧入,將刺激植入式心臟復律去顫器的採用。正在進行的研發活動,包括遠端監控和無引線設備的整合,正在進一步提高產品的有效性和可訪問性。此外,醫療保健提供者和設備製造商之間的策略合作以及對創新心臟解決方案不斷增加的監管支持將補充產業的擴張。
植入式心律轉復除顫器市場按產品、類型、最終用途和地區分類。
根據產品類型,預計 2024 年至 2032 年皮下 ICD 領域的行業佔有率將以 6.9% 的複合CAGR成長。這一成長可歸因於皮下植入式心律轉復除顫器(S-ICD) 因其微創性而受到越來越多的青睞。自然。感染風險的降低、患者舒適度的提高以及 S-ICD 技術的不斷進步將推動該產品在危及生命的心律不整治療中的採用。
由於對複雜心律不整管理的需求不斷增加,雙腔 ICD 類型細分市場的植入式心律轉復除顫器產業規模預計在 2024 年至 2032 年間將以 7% 的CAGR擴大。雙室 ICD 增強的感測能力、提高的檢測精度和最佳化的治療交付也將有助於滿足患有各種心臟病的患者的複雜需求。
從地區來看,2024 年至 2032 年間,歐洲植入式心律轉復除顫器產業規模的CAGR將達到6.1%。這一成長可歸因於人口老化、心血管疾病發生率的增加以及心臟設備的更高技術進步。此外,支持性醫療保健政策的訂定、預防心臟病學意識的提高以及醫療保健組織和設備製造商之間的策略合作將推動該地區的行業擴張。
Implantable cardioverter defibrillators market size is projected to expand at over 6.4% from 2024 to 2032. The increasing prevalence of cardiovascular diseases, especially arrhythmias and sudden cardiac arrests is fueling the demand for implantable cardioverter defibrillators (ICDs). The aging population and growing lifestyle-related risk factors is leading to rising advancements in ICD technology. For instance, in December 2023, the PROFID EHRA study was launched, representing the first clinical trial for reevaluating the standard practice of implanting defibrillators in heart attack survivors with heart failure.
The rising awareness about preventive healthcare measures coupled with the influx of favorable reimbursement policies will stimulate the adoption of implantable cardioverter defibrillators. The ongoing R&D activities, including the integration of remote monitoring and leadless devices is further enhancing the product effectiveness and accessibility. Additionally, strategic collaborations between healthcare providers and device manufacturers along with the increasing regulatory support for innovative cardiac solutions will complement the industry expansion.
The implantable cardioverter defibrillators market is segregated into product, type, end-use, and region.
Based on product type, the industry share from the subcutaneous ICDs segment is projected to rise at 6.9% CAGR from 2024 to 2032. The growth can be ascribed to the increasing preference for subcutaneous implantable cardioverter defibrillators (S-ICDs) due to their minimally invasive nature. The reduced infection risk, improved patient comfort, and increasing advancements in S-ICD technology will drive the product adoption in the management of life-threatening cardiac arrhythmias.
Implantable cardioverter defibrillators industry size from the dual-chamber ICDs type segment is estimated to expand at 7% CAGR between 2024 and 2032, owing to the increasing demand for sophisticated arrhythmia management. The enhanced sensing capabilities, improved detection accuracy, and optimized therapy delivery of dual chamber ICDs will also help address the complex needs of patients with various cardiac conditions.
Regionally, the Europe implantable cardioverter defibrillators industry size will depict 6.1% CAGR between 2024 and 2032. The growth can be attributed to the aging population, increasing incidence of cardiovascular diseases, and the higher technological advancements in cardiac devices. Moreover, the introduction of supportive healthcare policies, the rising awareness of preventive cardiology, and strategic collaborations between healthcare organizations and device manufacturers will drive the industry expansion across the region.